Pharmaceutical Law | IP Enforcement | Medical Safety On August 5, 2025, Danish pharmaceutical giant Novo Nordisk announced the launch of 14 new lawsuits in the United States against providers of unapproved compounded semaglutide—the active ingredient in its blockbuster weight-loss and diabetes treatments, Wegovy and Ozempic (Reuters). The litigation targets